press release Archives - Voltron Therapeutics

Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Completion of a Trial Protocol to Study its Self Assembling Vaccine to Target Prostate Stem Cell Antigen

Noah Kanfer2025-06-17T09:39:28-04:00

Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Completion [...]

Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Completion of a Trial Protocol to Study its Self Assembling Vaccine to Target Prostate Stem Cell AntigenNoah Kanfer2025-06-17T09:39:28-04:00

Voltron Therapeutics, a Lucius Partners Company, with the VIC at MGH Announces $5.88 Million Award from U.S. DoD

danny2024-01-31T15:12:09-05:00

Award will advance the Self-Assembling Vaccine Platform for rapid [...]

Voltron Therapeutics, a Lucius Partners Company, with the VIC at MGH Announces $5.88 Million Award from U.S. DoDdanny2024-01-31T15:12:09-05:00

Lucius Partners Portfolio Company Voltron Therapeutics, Inc Adds Manufacturing Expert to Scientific Advisory Board

danny2024-01-31T15:09:40-05:00

Globally recognized manufacturing and product supply expert Tibor [...]

Lucius Partners Portfolio Company Voltron Therapeutics, Inc Adds Manufacturing Expert to Scientific Advisory Boarddanny2024-01-31T15:09:40-05:00

Lucius Partners Portfolio Company Voltron Therapeutics Announces Robust Immunogenicity Data: Key Prostate Cancer Target

danny2023-09-06T15:53:23-04:00

Self Assembling Vaccine targets Prostate Stem Cell Antigen [...]

Lucius Partners Portfolio Company Voltron Therapeutics Announces Robust Immunogenicity Data: Key Prostate Cancer Targetdanny2023-09-06T15:53:23-04:00

Voltron Therapeutics, a Lucius Partners Company, with the VIC at MGH Announces $5.88 Million Award from U.S. DoD

danny2023-08-25T14:19:08-04:00

Voltron Therapeutics, a Lucius Partners Company, with the [...]

Voltron Therapeutics, a Lucius Partners Company, with the VIC at MGH Announces $5.88 Million Award from U.S. DoDdanny2023-08-25T14:19:08-04:00

Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Sponsored Research Agreement with the Massachusetts General Hospital, Harvard Medical School, to Initiate a Pre-clinical Immuno-Oncology Trial

Daniel Malowany2023-08-25T14:20:35-04:00

Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces [...]

Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Sponsored Research Agreement with the Massachusetts General Hospital, Harvard Medical School, to Initiate a Pre-clinical Immuno-Oncology TrialDaniel Malowany2023-08-25T14:20:35-04:00

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Poster Presentation at the Military Health System Research Symposium

Daniel Malowany2023-04-05T19:21:55-04:00

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, [...]

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Poster Presentation at the Military Health System Research SymposiumDaniel Malowany2023-04-05T19:21:55-04:00

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Lead Oncology Candidate (VTX-067) in an HPV Related Tumor Challenge Study

Daniel Malowany2023-04-05T20:03:51-04:00

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, [...]

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Lead Oncology Candidate (VTX-067) in an HPV Related Tumor Challenge StudyDaniel Malowany2023-04-05T20:03:51-04:00

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Industry Veteran Dr. Tony Hodges has Joined the Company as Senior Scientific Advisor

Daniel Malowany2023-04-05T18:58:29-04:00

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, [...]

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Industry Veteran Dr. Tony Hodges has Joined the Company as Senior Scientific AdvisorDaniel Malowany2023-04-05T18:58:29-04:00

Voltron Therapeutics, Inc., a Lucius Partners Company, Announces Initiation of Key Preclinical Study of VTX-067 in Immuno-Oncology

Daniel Malowany2023-04-05T13:22:39-04:00

Voltron Therapeutics, Inc., a Lucius Partners Company, Announces [...]

Voltron Therapeutics, Inc., a Lucius Partners Company, Announces Initiation of Key Preclinical Study of VTX-067 in Immuno-OncologyDaniel Malowany2023-04-05T13:22:39-04:00